Skip to main content
Fig. 3 | AMB Express

Fig. 3

From: Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

Fig. 3

The workflow of MNCP. The steps were as follows: (1) Nucleic acid was extracted from throat swab samples. (2) A mixture including nucleic acid, basic NASBA reaction reagents, primers, and molecular beacon probes was loaded into the micro/nanofluidic chip. (3) The loaded chip was placed into the RTisochip-A detector (CapitalBio, Beijing, China). (4) RNA was amplified based on the NASBA and the fluorescence intensity data were collected and analyzed using the software. (5) Results of detecting and subtyping of influenza A and B viruses were obtained. Fluorescent curves were plotted by detection time (X-axis) against fluorescent intensity (Y-axis) for influenza A(H1N1)pdm09, A(H3N2), and influenza B virus, respectively. A batch of the MNCP tests took about 1 h. MNCP: micro/nanofluidic chip platform; NASBA: nucleic acid sequence-based amplification

Back to article page